Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Monte Rosa’s MRT-6160 Enters Phase 2 Trial in Psoriatic Arthritis

By Public Technologies
  • Novartis initiated a second Phase 2 study of Monte Rosa Therapeutics’ MRT-6160 (DDY391) in active moderate to severe psoriatic arthritis.
  • The first patient visit triggers a $37.5 million milestone payment under the partners’ exclusive global development and commercialization license agreement.
  • The randomized, placebo-controlled Phase 2a/b trial will evaluate efficacy, safety, tolerability and dose response.
  • A Phase 2 trial in Sjögren’s disease began in August; additional Phase 2 study initiations could trigger further milestone payments.
  • Phase 1 showed sustained, dose-dependent VAV1 degradation exceeding 90% in peripheral blood T cells, with no serious adverse effects observed.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monte Rosa Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280700PRIMZONEFULLFEED9854312) on October 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.